Skip to main content
TipRanks
Go Ultimate75% OFF

So-Young International (SY) AI Stock Analysis

190 Followers
SY

So-Young International

(NASDAQ:SY)

Select Model
Rating:55Neutral
Price Target:$2.00â–¼(-0.99% Downside)
Action:reiterated
Date:09/06/26

The overall score is 55, reflecting a company in transition. The primary positive driver is a powerful operational turnaround in its aesthetic treatment business, as detailed in the latest earnings call, which is supported by bullish technical momentum. However, these strengths are significantly offset by a legacy of poor financial health, characterized by persistent net losses, negative cash flows, and a negative P/E ratio. The company's future hinges on the core clinic business's growth and margin expansion overcoming the drag from declining legacy segments.

Positive Factors
Aesthetic Treatment GrowthRapid, repeated growth in aesthetic treatment revenue shows strong demand and successful migration toward the company’s higher-growth clinic model. The tenth consecutive quarter of triple-digit growth, rising visits, and expanding users support durable operating scale over the next several quarters.
Negative Factors
Persistent Group LossesSo-Young remains loss-making at the group level, and management says the clinic business is still in a strategic investment stage. Continued losses limit internally funded growth and leave overall profitability dependent on successful execution of the clinic expansion and efficiency plans.

So-Young International (SY) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%SY-36.08%SPY+15.52%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$264.21M
Dividend Yield
―
Average Volume (3M)
515.45K
Price to Earnings (P/E)
-7.3
Beta (1Y)
1.07
Revenue Growth
30.18%
EPS Growth
61.28%
Country
US
Employees
2,348
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Information Services

So-Young International Business Overview & Revenue Model

Company Description

So-Young International Inc. manages a digital platform specializing in medical aesthetics and elective healthcare services, serving customers in the People's Republic of China and globally. This online ecosystem enables users to explore content, shar...

So-Young International Earnings Call Summary

Earnings Call Date:Aug 31, 2026(Q2-2026)|% Change Since:-15.83%|Next Earnings Date:May 30, 2019
Earnings Call SentimentPositive

The call was strongly positive. The company reported record group revenue, approximately 130% year-over-year aesthetic treatment growth, a 37% year-over-year reduction in net loss, improved gross margin, higher same-store sales, expanding clinic profitability and positive operating cash flow across most centers. Management also presented continued product, physician, supply chain and AI initiatives, along with strong revenue guidance for the next quarter. The main negatives were declines in non-clinic business lines, higher cost of revenues and operating expenses, and the continuation of a group-level net loss.

Positive Updates

Record Group Revenue and Strong Aesthetic Treatment Growth
Q2 aesthetic treatment revenue reached RMB 331.4 million, growing approximately 130% year-over-year and exceeding the upper end of guidance for the sixth consecutive quarter. Group revenue reached a quarterly record of RMB 505.2 million, up 33% year-over-year. Aesthetic treatment revenue grew approximately 103% excluding the 3 to 5 percentage points of revenue deferral from the loyalty program and systematic treatment protocols.

Negative Updates

Information and Reservation Services Revenue Decline
Revenue from information and reservation services fell 35% year-over-year to RMB 87.9 million, primarily due to a decrease in the number of medical service providers subscribing to the information services.

Company Guidance

For Q3 2026, So-Young expects revenues from aesthetic treatment services to be between RMB 352 million and RMB 362 million, representing year-over-year growth of 91.7% to 97.2%; it expects meaningful margin expansion at aesthetic centers, has raised its capacity utilization benchmark by 50% from 10 treatments per bed per day to 15, expects to see substantial continued improvement in clinic gross margins in Q3 and Q4 of this year, plans to roll out its first generation of fully intelligent centers in Q4 this year, and has a robust pipeline of new products over the next 2 years to help improve gross margin.

So-Young International Financial Statement Overview

Summary

Financial health is severely stressed. The income statement shows deep net losses and gross margins halved to 47.8%. Cash flow is critically weak, with four consecutive years of negative free cash flow and a -20.4% FCF margin in 2025. The balance sheet is deteriorating with shrinking equity, though leverage remains manageable. Overall, the company is burning cash and eroding shareholder value.

Income Statement

20Very Negative

Balance Sheet

40Negative

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.65B1.48B1.47B1.50B1.26B1.69B
Gross Profit759.68M707.86M899.11M953.69M864.58M1.36B
EBITDA-203.21M-182.19M-38.56M53.96M-39.99M63.39M
Net Income-256.54M-235.70M-589.53M21.28M-65.55M-8.37M
Balance Sheet
Total Assets2.65B2.65B2.74B3.21B3.20B3.33B
Cash, Cash Equivalents and Short-Term Investments876.69M936.96M1.19B1.33B1.57B1.74B
Total Debt379.00M299.90M239.88M145.77M71.26M105.89M
Total Liabilities1.05B981.44M776.43M653.25M590.00M813.33M
Stockholders Equity1.49B1.55B1.84B2.44B2.50B2.45B
Cash Flow
Free Cash Flow-302.01M-302.01M-88.18M-28.68M-128.58M39.23M
Operating Cash Flow-105.39M-105.39M-25.63M22.50M-112.87M84.29M
Investing Cash Flow-42.81M-42.81M257.04M-202.61M-572.21M339.82M
Financing Cash Flow-63.70M-63.70M-21.51M-100.02M-13.59M-216.74M

So-Young International Technical Analysis

Technical Analysis SentimentNegative
Last Price2.02

Price Trends

50DMA2.42Negative
100DMA2.21Negative
200DMA2.47Negative

Market Momentum

MACD-0.11Negative
RSI40.33Neutral
STOCH32.68Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SY, the sentiment is Negative. The current price of 2.02 is below the 20-day moving average (MA) of 2.08, below the 50-day MA of 2.42, and below the 200-day MA of 2.47, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 40.33 is Neutral, neither overbought nor oversold. The STOCH value of 32.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SY.

So-Young International Risk Analysis

So-Young International disclosed 86 risk factors in its most recent earnings report. So-Young International reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.Our business is subject to data privacy laws and regulations in jurisdictions other than China. Any failure or perceived failure to comply with such laws and regulations could have a material and adverse impact on our business, financial condition and results of operations.Q4, 2023

So-Young International Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SY against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PHRPHR69Neutral$787.68M73.693.01%―12.93%―
CCLDCCLD66Neutral$102.97M18.6424.48%―14.86%214.99%
GDRXGDRX65Neutral$1.21B67.682.61%―-1.83%-48.77%
AMWLAMWL57Neutral$202.17M-3.41-25.49%―-20.30%52.30%
TDOCTDOC56Neutral$1.60B-10.23-11.63%―-2.38%32.73%
SYSY55Neutral$203.24M-7.33-15.75%―30.18%61.28%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%100%200%SYCCLDTDOCPHRAMWLGDRXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SY and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SYSo-Young International2.02-1.47-42.12%
CCLDCarecloud, Inc.2.42-0.56-18.79%
TDOCTeladoc Inc.8.801.8025.71%
PHRPhreesia12.69-6.91-35.26%
AMWLAmerican Well Corporation11.747.72192.04%
GDRXGoodrx Holdings, Inc.3.560.7727.60%

So-Young International Corporate Events

So-Young International Posts Record Q2 2026 Revenue as Aesthetic Treatment Business Surges

Aug 31, 2026

For the second quarter ended June 30, 2026, So-Young reported total revenues of RMB505.2 million, up 33.4% year-on-year and reaching a record level, driven mainly by a 129.5% surge in aesthetic treatment services revenue to RMB331.4 million. Despite...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026